Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma

Journal of the National Cancer Institute

Volumn 84, Issue 24, 1992, Pages 1875-1887

  Weidner, Noel ^a   Folkman, Judah ^b   Pozza, Franco ^c   Bevilacqua, Pierantonio ^c   Allred, Elizabeth N ^d   Moore, Dan H ^e   Meli, Salvatore ^c   Gasparini, Giampietro ^c,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c St Bortolo Medical Centre   (Italy)

^d Statistical and Data Base Consulting ^*  (United States)

^e LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^f St Bortolo Regional Medical Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; DNA; ONCOPROTEIN; STEROID HORMONE; STEROID RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSCOPY; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMAN; LYMPHATIC METASTASIS; MICROCIRCULATION; MIDDLE AGE; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0027043136     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.24.1875     Document Type: Article

References (63)

1. Sigurdsson H, Baldetorp B, Boro A, et al: Indicators of prognosis in node-negative breast cancer. N Engl J Med 322:1045-1053, 1990
2. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991
3. Folkman J: What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 82:4-6, 1990
4. Blood CH, Zetter BR: Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim Biophys Ada 1032:89-118, 1990
5. Weidner N: The relationship of tumor angiogenesis and metastasis with emphasis on invasive breast carcinoma. In Advances in Pathology, vol 5. Chicago: Mosby-Yearbook, 1992, pp 101-122
6. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
7. Bosari S, Lee AK, DeLelus RA, et al: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
8. Kaldjian E, Jin L, Lloyd R: Immunohistochemical analysis of breast carcinomas: Correlation of estrogen and progesterone receptors, prolifcrative activity, tumor vascularity, and lymph node metastasis. Mod Pathol 5:14a, 1992
9. Sneioe N, Singletary E, Sahin A, et al: Multiparameter analysis of potential prognostic factors in node negative breast cancer patients. Modern Pathol 5:18a, 1992
10. Horak ER, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endotbelial cell adhesion molecule antibodies, as indicator of node métastases and survival in breast cancer. Lancet 340:1120-1124, 1992
11. Macchiarjni P, Fontanini G, Hardin MJ, et al: Relation of neovasculature to metastases of non-small-cell lung cancer. Lancet 340:145-146, 1992
12. American Joint Committee on Cancer: Manual for Staging of Cancer (3rd ed). Philadelphia: J. B. Lippincott Company, 1988, pp 149-154
13. Office of Medical Applications of Research, National Institutes of Health: Consensus Conference. Adjuvant chemotherapy of breast cancer. JAMA 254:3461-3463, 1985
14. Fisher ER, Greoorio RM, Fisher B: The pathology of invasive breast cancer: A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 9). Cancer 36:1-85, 1975
15. Bloom RIG, Richardson WW: Histologie grading and prognosis. Br J Cancer 11:359-377, 1957
16. Page DL, Anderson TJ: Vessel invasion. In Diagnostic Histopathol-ogy of the Breast. Edinburgh: Churchill-Livingstone, 1987, pp 283-284
17. Gasparini G, Meu S, Panizzoni GA, et al: Peritumoral lymphatic vessel invasion compared with DNA ploidy, prolifcrative activity, and other pathologic features as prognostic indicators in operable breast cancer. Breast Cancer Res Treat 20:195-204, 1991
18. Gasparini G, Bevilacqua P, Dal Fior S, et au Characterization of node-negative breast cancer by clinico-pathologic and biologic factors. Anticancer Res 10:205-208, 1990
19. Bevilacqua P, Gasparini G, Dal Fior S, et al: Immunocytochemi-cal determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patients. Oncology 47:313-317, 1990
20. Waterfield MD, Mayers EL, Stroobant P, et al: A monoclonal antibody to the human epidermal growth factor receptor. J Cell Biochem 20:149-161, 1982
21. Hsu SM, Raine L, Fänger H: A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin-complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75:734-738, 1981
22. Hedley DW, Friedlander ML, Taylor W, et al: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histocbem Cytochem 31:1333-1335, 1983
23. Vindelov LL, Christensen LI, Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow-cytometric DNA analysis. Cytometry 3:323-327, 1983
24. Baisch H, Gohde W, Linden WA: Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiât Environ Biophys 12:31-39, 1975
25. Frankfurt OS, Greco WR, Slocum HK: Proliferative characteristics of primary and metastatic human solid tumors by DNA flow cytometry. Cytometry 3:629-635, 1984
26. Guluck WJ, Berger MS, Bbnnet PL, et al: Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer 40:246-254, 1987
27. Gasparini G, Guluck WJ, Bevilacqua P, et al: Human breast cancer: Prognostic significance of the expression of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992
28. Wright C, Anous B, Nicholson S, et au Expression of c-erbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
29. Garcia M, Salazar-Retana G, Richer G: Immunocytochemical detection of the estrogen-regulated 52, 000 mol wt protein in primary breast cancers but not in normal breast and uterus. J Clin Endocrinol Metab 59:564-566, 1984
30. Garcia M, Capony F, Derocq D: Characterization of monoclonal antibodies to the estrogen-regulated MR 52, 000 glycoprotein and their use in MCF7 cells. Cancer Res 45:709-716, 1985
31. Gasparini G, Bevilacqua P, Meu S, et al: Immunocytochemical determination of pro-cathepsin D: A significant independent prognostic indicator in early-stage breast cancer. Breast Dis. In press
32. EORTC Breast Cancer Cooperative Group: Standards for the assessment of estrogen receptor in human breast cancer. Eur J Cancer 9:379-381, 1973
33. Gasparini G, Pozza F, Dittadi R, et al: Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer. J Cancer Res Clin Oncol 118:557-563, 1992
34. Scatchard G: The attraction of proteins for small molecules and ions. Ann NY Acad Sci 51:609-672, 1949
35. Gasparini G, Dal Fior S, Pozza F, et al: Correlation of growth fraction by Ki-67 immunohistochemistry with histologie factors and hormone receptors in operable breast carcinoma. Breast Cancer Res Treat 14:329-336, 1989
36. Gasparini G, Pozza F, Bevilacqua P, et al: Growth fraction (Ki-67 antibody) determination in early-stage breast carcinoma: Histologie, clinical, and prognostic correlations. The Breast 1:92-99, 1992
37. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
38. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
39. Thor AD, Moore DH, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
40. Cox DR: Analysis of Binary Data. London: Methuen, 1970
41. Cox DR: Regression models and life tables (with discussion). J R Stat Society Ser B 34:187-220, 1972
42. Cox DR, Oakes D: Analysis of Survival Data. London: Chapman & Hall, 1984
43. Colton T: Regression and correlation. In Statistics in Medicine, 1st ed. Boston: Little, Brown, 1974
44. Gimbrone MA Jr, Leapman SB, Cotran RS, et al: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 136:261-276, 1972
45. Sutherland RM, McCredie JA, Inch WR: Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst 46:113-120, 1971
46. Gimbrone MA, Cotran RS, Leapman S, et al: Tumor growth neovascularization: An experimental model using rabbit cornea. J Natl Cancer Inst. 52:413-427, 1974
47. Folkman J, Klaosbrun M: Angiogenic factors. Science 235:442-447, 1987
48. Folkman J, Watson K, Inober D, et al; Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989
49. Liotta LA, Satdel MG, Kletnerman J: The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 36:889-894, 1976
50. Folkman J: Tumor angiogenesis. In Cancer Medicine (Holland JF, Frei E, Bast RC, et al, eds), 3rd ed, Chap 11. Philadelphia: Lea & Febiger. In press
51. Kerbel RS, Waohorne C, Korczak B, et al: Clonal dominance of primary tumours by metastatic cells: Genetic analysis and biological implications. Cancer Surv 7:597-629, 1988
52. Weiss L: Biophysical aspects of the metastatic cascade. In Fundamental Aspects of Metastasis (Weiss L, ed). Amsterdam: North Holland, 1976, pp 51-70
53. Liotta LA, Stracke ML: Tumor invasion and métastases: Biochemical mechanisms. Cancer Treat Res 40:223-238, 1988
54. Liotta LA, Kletnerman J, Satdel GM: Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary métastases following tumor implantation. Cancer Res 34:997-1004, 1974
55. Kandel J, Bossy-Wetzel E, Radvanyi F, et al: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 66:1095-1104, 1991
56. Naoy JA, Brown LF, Senoer DR, et al; Pathogenesis of tumor stroma generation: A critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Ada 948:305-326, 1989
57. Moscatelli D, Gross J, Rifktn D: Angiogenic factors stimulate plasminogen activator and collagenase production by capillary endothelial cells. J Cell Biol 91:201a, 1981
58. Gould VE, Ltnnoila LI, Memoli VA, et al: Neuroendocrine components of the bronchopulmonary tract: Hyperplasias, dysplasias, and neoplasms. Lab Invest 49:519-537, 1983
59. Ingle JN: Assessing the risk of recurrence in breast cancer. N Engl J Med 322:329-331, 1990
60. Fisher B, Redmond C, Dimitrov NV: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 320:473-478, 1989
61. Fisher B, Costanttno J, Redmond C: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
62. Mansour EG, Gray R, Shattla AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med 320:485-490, 1989
63. The Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989